Parkman Healthcare Partners LLC Boosts Stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Parkman Healthcare Partners LLC grew its position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 2.8% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 260,226 shares of the company’s stock after acquiring an additional 7,029 shares during the period. Parkman Healthcare Partners LLC’s holdings in Eton Pharmaceuticals were worth $1,561,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of ETON. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Eton Pharmaceuticals during the 3rd quarter worth approximately $54,000. Renaissance Technologies LLC grew its stake in Eton Pharmaceuticals by 63.8% during the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock worth $350,000 after buying an additional 41,469 shares during the period. Stonepine Capital Management LLC acquired a new stake in shares of Eton Pharmaceuticals in the second quarter worth $362,000. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Eton Pharmaceuticals by 86.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock valued at $390,000 after acquiring an additional 30,167 shares during the period. Finally, Thompson Siegel & Walmsley LLC acquired a new position in Eton Pharmaceuticals during the 2nd quarter worth approximately $420,000. 27.86% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Eton Pharmaceuticals

In other Eton Pharmaceuticals news, major shareholder Opaleye Management Inc. bought 16,852 shares of the stock in a transaction that occurred on Friday, October 4th. The shares were purchased at an average cost of $6.77 per share, for a total transaction of $114,088.04. Following the transaction, the insider now directly owns 2,720,000 shares in the company, valued at $18,414,400. The trade was a 0.62 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have purchased 85,600 shares of company stock worth $462,674. 14.89% of the stock is currently owned by company insiders.

Eton Pharmaceuticals Stock Down 5.1 %

Shares of NASDAQ:ETON opened at $11.82 on Wednesday. The firm has a 50-day simple moving average of $8.92 and a 200 day simple moving average of $5.68. Eton Pharmaceuticals, Inc. has a fifty-two week low of $3.03 and a fifty-two week high of $13.98. The company has a market cap of $305.43 million, a PE ratio of -53.73 and a beta of 1.39.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Craig Hallum boosted their target price on shares of Eton Pharmaceuticals from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, October 28th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target (up from $11.00) on shares of Eton Pharmaceuticals in a report on Tuesday, November 26th.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.